1
|
Okui T, Hiasa M, Ryumon S, Ono K, Kunisada Y, Ibaragi S, Sasaki A, Roodman GD, White FA, Yoneda T. The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone. J Bone Oncol 2020; 26:100330. [PMID: 33204606 PMCID: PMC7649349 DOI: 10.1016/j.jbo.2020.100330] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Revised: 10/06/2020] [Accepted: 10/06/2020] [Indexed: 02/06/2023] Open
Abstract
The 4T1 mouse breast cancer injected in tibiae induced bone pain. The 4T1 breast cancer secreted high mobility group box 1 (HMGB1) that promotes axogenesis of sensory neurons. Bone pain was reduced by HMGB1 antibody and an antagonist for the receptor for advanced glycation end products.
Bone pain is a common complication of breast cancer (BC) bone metastasis and is a major cause of increased morbidity and mortality. Although the mechanism of BC-associated bone pain (BCABP) remains poorly understood, involvement of BC products in the pathophysiology of BCABP has been proposed. Aggressive cancers secrete damage-associated molecular patterns (DAMPs) that bind to specific DAMP receptors and modulate cancer microenvironment. A prototypic DAMP, high mobility group box 1 (HMGB1), which acts as a ligand for the receptor for advanced glycation end products (RAGE) and toll-like receptors (TLRs), is increased in its expression in BC patients with poor outcomes. Here we show that 4T1 mouse BC cells colonizing bone up-regulate the expression of molecular pain markers, phosphorylated ERK1/2 (pERK) and pCREB, in the dorsal root ganglia (DRGs) innervating bone and induced BCABP as evaluated by hind-paw mechanical hypersensitivity. Importantly, silencing HMGB1 in 4T1 BC cells by shRNA reduced pERK and pCREB and BCABP with decreased HMGB1 levels in bone. Further, administration of a neutralizing antibody to HMGB1 or an antagonist for RAGE, FPS-ZM1, ameliorated pERK, pCREB and BCABP, while a TLR4 antagonist, TAK242, showed no effects. Consistent with these in vivo results, co-cultures of F11 sensory neuron-like cells with 4T1 BC cells in microfluidic culture platforms increased neurite outgrowth of F11 cells, which was blocked by HMGB1 antibody. Our results show that HMGB1 secreted by BC cells induces BCABP via binding to RAGE of sensory neurons and suggest that the HMGB1/RAGE axis may be a potential novel therapeutic target for BCABP.
Collapse
Key Words
- 4T1 mice, mice intratibially inoculated with 4T1 BC cells
- 4T1/sh HMGB1 mice, mice intratibially inoculated with 4T1 BC/sh HMGB1 cells
- 4T1/sh control mice, mice intratibially inoculated with 4T1 BC/sh control cells
- ALP, alkaline phosphatase
- BC, breast cancer
- BCABP, breast cancer-associated bone pain
- Bone pain
- Breast cancer
- CGRP, calcitonin gene-related peptide
- CM, conditioned medium
- CREB, cyclic AMP-responsive element-binding protein
- DAMP, damage-associated molecular pattern
- DRG, dorsal root ganglion
- DbcAMP, dibutyryl cyclic AMP
- ERK, extracellular signal-regulated kinase
- HMGB1
- HMGB1, high mobility group box 1
- M-CSF, macrophage colony-stimulating factor
- MNOCs, multinucleated osteoclast-like cells
- RAGE
- RAGE, receptor for advanced glycation end products
- RANKL, receptor activator of NF-κB ligand
- SN, sensory neuron
- Sensory neurons
- TRAP, tartrate-resistant acid phosphatase
- TRL, toll-like receptor
- pCREB, phosphorylated CREB
- pERK, phosphorylated ERK
Collapse
Affiliation(s)
- Tatsuo Okui
- Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.,Department of Medicine, Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Masahiro Hiasa
- Department of Biomaterials and Bioengineerings, University of Tokushima Graduate School of Dentistry, Tokushima, Japan.,Department of Medicine, Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Shoji Ryumon
- Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Kisho Ono
- Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Yuki Kunisada
- Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Soichiro Ibaragi
- Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - Akira Sasaki
- Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
| | - G David Roodman
- Department of Medicine, Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.,The Rodebusch VA, Indianapolis, IN, USA
| | - Fletcher A White
- Department of Anesthesia, Paul and Carole Stark Neurosciences Research Institute, Indianapolis, IN, USA
| | - Toshiyuki Yoneda
- Department of Medicine, Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.,Department of Cellular and Molecular Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan
| |
Collapse
|